Clinical trials: Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Cancer, Breast Cancer

Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors

• Recruiting
• Age: 8 to 85 years
• Phase 1/2
• Injection or infusion

This Phase 1/2 study evaluates the safety, feasibility, and preliminary anti-tumor activity of allogeneic donor-derived CAR-NK cells in participants with advanced solid tumors.

Conditions

Cancer, Breast Cancer, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (Locally Advanced or Metastatic)

Trial name

SELECT-CAR-NK (NCT07410494)

Testing

EB-SELECT Single-Target CAR-NK Cells, Dual-Target Antigen-Selected CAR-NK

Where

China

Volunteers

85 people

Sponsor

Essen Biotech